Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility

Merck (MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibostolimab, its investigational anti-TIGIT antibody, as adjuvant treatment for patients with resected high-risk melanoma.Data from a pre-planned analysis of the study called KeyVibe-010 showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria. A higher rate of patients discontinued all adjuvant therapy ...